Filana Therapeutics Inc.
Filana Therapeutics Inc. (FLNA): 268 pipeline candidates · 25 upcoming catalysts · ~29 mo cash runway · 130 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
29.4 months
D/E 0.59 · 0% dilution
Lead: Phase 3
268 candidates
25 upcoming, next in ~5d
N/A
A transparent, data-derived signal for Filana Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$59.4M
Cash
$86.6M
Quarterly Burn
$8.9M
Runway
29.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (268 candidates)
| Drug | Phase |
|---|---|
| 6-Mercaptopurine | Phase 3 |
| AB248 | Phase 1 |
| Acalabrutinib | Phase 2 |
| ACE1831 | Phase 1 |
| Acetaminophen | Phase 4 |
| Acetaminophen 1000 mg/d | Phase 4 |
| Acetaminophen 325Mg Tab | Phase 4 |
| Acetaminophen 4000 mg/d | Phase 4 |
| Acetaminophen 500Mg Tab | Phase 4 |
| Acetylcysteine | Phase 2 |
Showing 10 of 268 candidates. Sign up for full pipeline.
Upcoming Catalysts (25)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
100
Total value held
$26.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,861,886 | $6.5M |
| marshall wace, llp | 2,012,543 | $3.4M |
| two sigma investments, lp | 1,988,814 | $3.4M |
| blackrock, inc. | 1,414,514 | $2.4M |
| susquehanna international group, llp | 749,178 | $1.3M |
| geode capital management, llc | 596,242 | $1.0M |
| d. e. shaw & co., inc. | 559,205 | $945K |
| jane street group, llc | 328,564 | $555K |
| renaissance technologies llc | 326,759 | $552K |
| citadel advisors llc | 311,100 | $526K |
Showing top 10 of 100 institutional holders of Filana Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Filana Therapeutics Inc.'s pipeline?
Filana Therapeutics Inc. (FLNA) has 268 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Filana Therapeutics Inc.'s lead drug candidate?
Filana Therapeutics Inc.'s most advanced tracked candidate is 6-Mercaptopurine (Phase 3) for Acute,Leukemia, Lymphoid; Drug/Agent Toxicity by Tissue/Organ.
What is Filana Therapeutics Inc.'s next catalyst?
Filana Therapeutics Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells i" — expected June 23, 2026.
What is Filana Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Filana Therapeutics Inc. has approximately 29.4 months of cash runway.
What is Filana Therapeutics Inc.'s market capitalization?
Filana Therapeutics Inc.'s market capitalization is approximately $59.4M.
Get the full picture on Filana Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.